Monday, July 22, 2013 8:00:53 AM
If NNVC builds it, they will come...
Dr. Seymour understands the concept of "time is money" very well. Here are some of the most noticeable points I picked up from his recent NNVC-RedChip video interview: “We have the money.”, “No failures in 5,000 animals….We are agnostic as to the host.”, “As long as you have a virus in your circulation, we destroy it.”, “Multi-billion dollar market cap? Oh, easily.“ Dr. Seymour's demeanor is one of controlled giddiness. He exudes confidence when he says, "...we are on a path, it is like being on a track,.." ---
From a recent "Tomorrow in Review" - Addisson Wiggin writes, "I get up in the morning," our friend Juan Enriquez told us during an interview one day late in 2011, "I read the paper and see all the bad things going on with the debt, deficits, wars and the economy. Then, I step into a lab and see all the potential breakthroughs the scientists I work with are about to unveil."
"In his day, Schumpeter - a prophet of innovation, witnessed the triumphs of radio, frozen food, the gas stove and the traffic light -- all technologies we currently take for granted. But his observations of "how" these innovations come about remain as relevant today as ever."
"Existing structures and all the conditions of doing business," Schumpeter concluded, "are always in a process of change. Every situation is being upset before it has had time to work itself out. Economic progress, in a capitalist society, means turmoil."
"In an ideal world, entrepreneurs, innovators, the risks takers, would be free to embrace the turmoil at their own peril. But no... in the real world, we have the meddlers, the world improvers, (ahem) bureaucrats." --- Hence, the random "Black Swan" catastrophic event.
The following are some catalysts/events that I extracted from another 2013 NNVC - RedChip video: ---
- FluCide® could achieve "Blockbuster Status" as well as other anti-viral drugs in the pipeline, in short order ~ 2015
- Strong IP protection; well over 100 countries expected to approve patent applications by 4Q 2013; patents issued as "first in class" with no prior art
- Large global market for Nanoviricides™, north of 70B; platform technology to rapidly create anti-viral drugs that result in destruction of specific virus
We also heard from the most recent NNVC-RedChip video presentation that people, entrepreneurs, the risks takers, were offering money to Dr. Seymour. The cGMP plant is not ready and validated, no human trials, yet people are already offering money to Dr. Seymour! They offer money because they get the nano-science behind NNVC, because of their vision of a grand business opportunity and/or perhaps, because of their wise, magnanimous foresight of another opportunity that will also benefit mankind.
Once the cGMP pilot plant is complete the Project Management group will continue steering a series of activities forward according to a timeline. The completion of the cGMP pilot plant in 4Q 2013 will be a milestone among others.
Some of the known Catalysts are: ---
Approval for DengueCide® orphan status ~ 3Q 2013
Well over 100 countries to approve "first in class" patent applications ~ 4Q 2013
Milestones -
-cGMP/R&D Center Shelton CT integration completes ~ 4Q 2013
-Commision new cGMP plant ~ 4Q 2013 (equipment moved in/3 identical test batches)
-Receive initial results toxicology studies FluCide ~ 4Q 2013
-Prepare IND for submission to regulatory authorities ~ 4Q 2013
Other guesstimated catalysts -
FluCide® production of test "identical" batches begins ~ 1Q 2014
FluCide® human trials Phase I/IIa begin ~ 3Q 2014
FluCide® human trials Phase IIb/III ~ 1H 2015
More guesstimates:
Potential for blockbuster drugs in pipeline begins realization could very well happen 1H 2015; If Allan's (www.allantrends.com) NNVC's nav estimation is correct (NNVC's nav at $100/share) it could quickly become a reality in 2015. Do you recall Dr. Seymour makes mention of some phase(s)/human trials taking only a "few short months".
A time will come, soon, when you will hear others in astonishment, asking, "...when did these ball players get here?"
Watch the video (above...known catalysts...), as many times as necessary. Do you read the same information from this video as I do? Do you see the same up and coming events for NNVC as I do? Will Big Pharma act in anticipation of results of Phase I or will they act after Phase I? My guesstimates are exactly that, guesses, based on a seasoned Project Management group, derived from Dr. Seymour's phrase, "... we are on a path, it is like being on a track,...", like a train of events, making scheduled stops, but coming our way on-time.
Dr. Seymour understands the concept of "time is money" very well. Here are some of the most noticeable points I picked up from his recent NNVC-RedChip video interview: “We have the money.”, “No failures in 5,000 animals….We are agnostic as to the host.”, “As long as you have a virus in your circulation, we destroy it.”, “Multi-billion dollar market cap? Oh, easily.“ Dr. Seymour's demeanor is one of controlled giddiness. He exudes confidence when he says, "...we are on a path, it is like being on a track,.." ---
--- Moreover, NNVC's CEO is humbly frugal!
From a recent "Tomorrow in Review" - Addisson Wiggin writes, "I get up in the morning," our friend Juan Enriquez told us during an interview one day late in 2011, "I read the paper and see all the bad things going on with the debt, deficits, wars and the economy. Then, I step into a lab and see all the potential breakthroughs the scientists I work with are about to unveil."
"In his day, Schumpeter - a prophet of innovation, witnessed the triumphs of radio, frozen food, the gas stove and the traffic light -- all technologies we currently take for granted. But his observations of "how" these innovations come about remain as relevant today as ever."
"Existing structures and all the conditions of doing business," Schumpeter concluded, "are always in a process of change. Every situation is being upset before it has had time to work itself out. Economic progress, in a capitalist society, means turmoil."
"In an ideal world, entrepreneurs, innovators, the risks takers, would be free to embrace the turmoil at their own peril. But no... in the real world, we have the meddlers, the world improvers, (ahem) bureaucrats." --- Hence, the random "Black Swan" catastrophic event.
The following are some catalysts/events that I extracted from another 2013 NNVC - RedChip video: ---
---
- FluCide® could achieve "Blockbuster Status" as well as other anti-viral drugs in the pipeline, in short order ~ 2015
- Strong IP protection; well over 100 countries expected to approve patent applications by 4Q 2013; patents issued as "first in class" with no prior art
- Large global market for Nanoviricides™, north of 70B; platform technology to rapidly create anti-viral drugs that result in destruction of specific virus
We also heard from the most recent NNVC-RedChip video presentation that people, entrepreneurs, the risks takers, were offering money to Dr. Seymour. The cGMP plant is not ready and validated, no human trials, yet people are already offering money to Dr. Seymour! They offer money because they get the nano-science behind NNVC, because of their vision of a grand business opportunity and/or perhaps, because of their wise, magnanimous foresight of another opportunity that will also benefit mankind.
Once the cGMP pilot plant is complete the Project Management group will continue steering a series of activities forward according to a timeline. The completion of the cGMP pilot plant in 4Q 2013 will be a milestone among others.
Some of the known Catalysts are: ---
---
Approval for DengueCide® orphan status ~ 3Q 2013
Well over 100 countries to approve "first in class" patent applications ~ 4Q 2013
Milestones -
-cGMP/R&D Center Shelton CT integration completes ~ 4Q 2013
-Commision new cGMP plant ~ 4Q 2013 (equipment moved in/3 identical test batches)
-Receive initial results toxicology studies FluCide ~ 4Q 2013
-Prepare IND for submission to regulatory authorities ~ 4Q 2013
Other guesstimated catalysts -
FluCide® production of test "identical" batches begins ~ 1Q 2014
FluCide® human trials Phase I/IIa begin ~ 3Q 2014
FluCide® human trials Phase IIb/III ~ 1H 2015
More guesstimates:
Potential for blockbuster drugs in pipeline begins realization could very well happen 1H 2015; If Allan's (www.allantrends.com) NNVC's nav estimation is correct (NNVC's nav at $100/share) it could quickly become a reality in 2015. Do you recall Dr. Seymour makes mention of some phase(s)/human trials taking only a "few short months".
A time will come, soon, when you will hear others in astonishment, asking, "...when did these ball players get here?"
We live in the "Age of Information". Those ball players are, for now, ghosts amongst us however, you can rest assured that once that cGMP pilot plant is built, ready, validated, we will start to see them and others will come.
Watch the video (above...known catalysts...), as many times as necessary. Do you read the same information from this video as I do? Do you see the same up and coming events for NNVC as I do? Will Big Pharma act in anticipation of results of Phase I or will they act after Phase I? My guesstimates are exactly that, guesses, based on a seasoned Project Management group, derived from Dr. Seymour's phrase, "... we are on a path, it is like being on a track,...", like a train of events, making scheduled stops, but coming our way on-time.
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
